Expertise & Services

Expertise

The Clinical Trials Service at PC-TRiADD builds on more than 20 years of experience in conducting superior quality clinical trials in a variety of indications. Our highly-qualified team of investigators and support staff include:

  • Four full-time urologists
  • Three full-time medical oncologists
  • Nine full-time clinical trial coordinators
  • Six registered nurses
  • Three regulatory affairs assistants
  • Administrative support staff

Services

Our core services include:

Clinical Trials:

  • Coordination of Phase I though III Clinical Trials
  • Pharmacokinetic, pharmacodynamic and biomarker studies
  • Proof of concept trials
  • Standardized protocols for adjuvant drug studies prior to radical prostatectomy (allowing tissue analysis following drug exposure)
  • Safety/efficacy studies with single agent or combination therapies
  • Long term surveillance studies
  • QOL and outcome studies
  • Development of clinical trial protocols
  • Preparation of regulatory and ethical documentation for submission to health Canada and Institutional Review Boards (IRBs)
  • Negotiation of Clinical Trial Agreements and Budgets
  • Development of study specific SOPs
  • Collection, entry, processing and analysis of clinical trials data and patient derived samples
    • Experience with both paper and electronic CRFs
  • Preparation of clinical study reports
  • Access to national and international multi-centre networks for GU tumor clinical trials

Clinical Assay Laboratory:

  • Biomarker and assay development
  • Human CTC assays
  • Human plasma and serum ELISA assays: single and multiplex

News

Jul 26 2017

Dr. Zoubeidi awarded PCC-Movember Translation Acceleration Grant

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.

Read more